Powering equity in cancer care through digital health
Dr Jeffrey Ross presents at ecancer's Milan Summit on Precision Medicine 2018 about the uses and limitations of NGS in precision medicine.
He highlights important limiting factors and examples of mutations which require highly sensitive technology.
He also goes in to detail regarding the FoundationOne assay.
Overall, Dr Ross encourages the marrying of clinical and genomic data to drive discovery in cancer research.
The webcast has been supported by an unrestricted educational grant from Roche Foundation Medicine
Powering equity in cancer care through digital health
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
GIST tumours and soft tissue sarcomas
Relapsed refractory multiple myeloma
Social determinants of health in primary care
Choosing Wisely in pathology
Choosing Wisely in radiology Tanzania
Lung cancer screening and treatment in the Philippines